News Teva files orphan blockbuster hope in tardive dyskinesia SD-809 will be vital for Teva if approved.
News Apitope aims to bounce back from MS setback Biotech looks for funding and long-term development partner
News Celgene to file potential MS blockbuster this year Success with ozanimod would justify $7.2 billion outlay for Receptos.
News Takeda to challenge GW Pharma with epilepsy deal Takeda makes epilepsy deal as GW prepares for US filing.
News Neurocrine pays $2.9bn for Soleno and extreme hunger drug Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
